Join more than 165,000 subscribers and keep yourself informed with the latest financial news, insights and expert analysis to help you understand what really matters when it comes to your finances.
You are now subscribed
Your newsletter sign-up was successful
Want to add more newsletters?
An account already exists for this email address, please log in.
Shares in focus: Ceramic renaissance at Portmeirion
Pottery firm Portmeirion is leading a renaissance for Britain’s once-dominant ceramics industry, says Alex Williams.
Plates and saucers are flying at pottery firm Portmeirion (LSE: PMP). The firm is listed on Aim and is now leading a renaissance for Britain's once-dominant ceramics industry, reporting seven consecutive years of record growth.
Portmeirion, founded in 1960 and named after the idyllic Welsh village, bought two of the UK's best-known ceramics brands, Spode and Royal Worcester, in the downturn of 2009. Since then the shares have taken off, as consumers in America and Asia have gone crazy for its growing range of dainty patterned ceramics.
Portmeirion makes porcelain, bone china and earthenware goods at its factory in Stoke-on-Trent. It recently spent £1.5m on a new kiln and is turning out 170,000 pieces per week, double its production levels in 2009. It has a showroom on Madison Avenue in New York and sells more in America than in the UK.
Start your trial of MoneyWeek today
Get unparalleled financial insight, analysis and expert opinion you can profit from.
Sign up for MoneyWeek’s free twice-daily newsletter.
Join more than 165,000 subscribers and keep yourself informed with latest financial news, insights and expert analysis to help you understand what really matters when it comes to your finances.
Join more than 165,000 subscribers and keep yourself informed with latest financial news, insights and expert analysis to help you understand what really matters when it comes to your finances.
The company's floral designs are also a big hit in Asia, with sales rocketing in India and China. South Korea is another big buyer, accounting for a quarter of the business. Total revenue jumped 12% last year to £69m, with full-year profit of £8.6m. Online orders are growing even more rapidly, up 27% last year to £2.5m. And sales for the current year are already up, according to a recent statement.
Portmeirion makes 80% of its pieces in England, but some are also made in China. That caused problems in 2013, when the EU introduced swingeing new anti-dumping taxes on ceramics imported from the country, forcing Portmeirion to shift part of its production to Bangladesh. Despite the added cost of more than £400,000, it still ended the year with a record profit.English bric-a-brac is in right now (think Downton Abbey and The Great British Bake Off).
That could change and consumers in the US and Korea might follow a different fad, stalling Portmeirion's growth rate. Its shares are trading at 16 times earnings and a 2.7% dividend yield, pricing in much of the good news.
But on both counts, Portmeirion is still cheaper than Churchill China, its closest listed competitor, which turns over less each year. Portmeirion's profit margins are higher and it is also debt-free, with £11.1m in cash on the balance sheet. It is difficult to find a crack in the company.
And the rest
Swipe to scroll horizontally
BAE Systems
BAE will benefit from a new $80bn bomber project (Shares), 494p
Cape
The order book is up and the shares yield 6% (Times), 242p
FDM
Software firm FDM is growing and "flush with cash" (Shares), 540p
The Gym
The discount gym operator is rolling out new sites this year (Shares), 232p
Hochschild
Costs are falling and precious metal prices are rising (Investors Chronicle), 89p
Kier
Acquisitions are paying off but the shares are cheap (The Times), 1299p
Smiths Group
Results were mixed but the medical business is strong (Investors Chronicle), 1072p
Dechra Pharma
Dechra has bought a business in the US that barely breaks even (Times), 1168p
Gulf Keystone
The firm is weighed down by debt and interest payments (Telegraph), 9.4p
GW Pharma
Its shares have spiked on drug test results; that may be premature (Shares), 507p
Inchcape
Margins are falling; the firm's outlook is cautious (Times), 725p
Spire Healthcare
CEO Rob Roger is leaving and a takeover isn't forthcoming (Times), 349p
Sign up for MoneyWeek's newsletters
Join more than 165,000 subscribers and keep yourself informed with the latest financial news, insights and expert analysis to help you understand what really matters when it comes to your finances.
